An Observational Study of Lung Cancer Related Symptoms and Disease Control Rate in Patients With Non-Small Cell Lung Cancer Receiving First-Line Platinum-Based Chemotherapy With or Without Avastin (Bevacizumab)
Completed
- Conditions
- Non-Squamous Non-Small Cell Lung Cancer
- Registration Number
- NCT01358942
- Lead Sponsor
- Hoffmann-La Roche
- Brief Summary
This prospective observational study will evaluate the evolution of lung cancer related symptoms and their correlation with the disease control rate (complete response, partial response and stable disease) in patients with non-small cell lung cancer initiating first-line treatment with standard platinum-based chemotherapy with or without Avastin (bevacizumab). Data will be collected from each patient at baseline and after 4-6 cycles of chemotherapy.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 156
Inclusion Criteria
- Adult patients, >/= 18 years of age
- Histologically or cytologically confirmed non-small cell lung cancer
- Initiating first-line treatment with standard platinum-based chemotherapy, with or without bevacizumab
Read More
Exclusion Criteria
- Contraindications to the use of platinum-based chemotherapy
Read More
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Change in lung cancer related symptoms (LCSS questionnaire) up to approximately 6 months (4-6 cycles of chemotherapy) Correlation of lung cancer related symptoms and disease control rate (complete response, partial response, stable disease according to RECIST criteria) approximately 2 years
- Secondary Outcome Measures
Name Time Method Frequency/severity of lung cancer related symptoms (LCSS questionnaire) approximately 2 years